Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Keros Therapeutics, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
kerostx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Keros Therapeutics announced a $20 million development milestone payment from Takeda Pharmaceuticals triggered by the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for elritercept in myelofibrosis patients, marking significant progress in their collaboration.
Key Takeaways
Keros received a $20 million milestone payment from Takeda upon first patient dosing in Phase 3 ELRiSE MF trial
The trial evaluates elritercept versus placebo in myelofibrosis and anemia patients on ruxolitinib therapy
1 more takeaway
Related Filings (1)
1 more filing from Keros Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Keros Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.